EDA and type 1 diabetes mellitus: APX3330 treatment significantly promotes M2 macrophage polarization as indicated by decreased ED1 (M1 macrophage marker) and increased CD163 (M2 macrophage marker) in the IBZ of T1DM stroke rats (p<0.05, n=7/group, Fig. 4A-B).